Ubiquitin carboxyl-terminal esterase-L1 (UCHL1), or gene product 9.5 (PGP9.5), belongs to a gene family that hydrolyzes small C-terminal adducts of ubiquitin to generate the monomers. The expression of UCHL1/PGP9.5 is highly specific to neurons and to cells of the diffuse neuroendocrine system as well as their tumors, and has been linked to neurodegenerative disease in humans. A group at Johns Hopkins used UCHL1 antibody to test the potential for elevated serum UCHL1 levels as an effective biomarker for brain injury in cardiac surgical patients on hypothermic circulatory arrest (HCA) and cardiopulmonary bypass (CPB) (1).
Immunohistochemistry: UCHL1 Antibody
Another study used UCHL1 antibody to investigate the efficacy of temperature management in reducing brain damage after an acute subdural hematoma (SDH) in a rat model (2). That group found that early hypothermia (temperature reduced 30 minutes prior to craniotomy) was significantly more effective as a neuroprotectant than late hypothermia (reduced 30 minutes after decompression). Researchers have also used UCHL1 antibody to show that UCHL1 overexpression decreased levels of Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and amyloid B (AB) through accelerated degradation and amyloid precursor protein (APP) processing (3). A 3D neurohistology imaging of the human ileum required use of the UCHL1 antibody and demonstrated that optical clearing could improve imaging depth and signal-to-noise ratios (SNR) (4).
Novus Biologicals offers various UCHL1 reagents for your research needs including:
